Business Wire

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last ...
News Medical

Breakthrough discovery could boost stem-cell transplants by improving cell mobilization

A discovery by a three-member Albert Einstein College of Medicine research team may boost the effectiveness of stem-cell transplants, commonly used for patients with cancer, blood disorders, or ...
ascopubs.org

Peripheral Blood Stem-Cell Mobilization and Collection Practices in Pediatric Patients With CNS and Solid Tumors

Consistent Trophoblast Cell Surface Antigen 2 Positivity in Tracheobronchial Adenoid Cystic Carcinoma: Expanding Antibody-Drug Conjugate Opportunities in Rare Thoracic Tumor We sought to evaluate PBSC ...
Yahoo Finance

BLRX: Stem Cell Mobilization Presentation at ASH

BioLineRx Ltd. (NASDAQ:BLRX) reported third quarter 2025 results, producing license revenues of $427,000. Following the September announcement of the joint venture (JV) with Hemispherian, the JV has ...
Yahoo Finance

New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting

REDWOOD CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that ...